IRIS Wellness Labs (IWL) is a subsidiary of IRIS Biotechnologies (IRSB) Inc. IWL provides a multitude of tests and services, which includes but is not limited to DNA sequencing, gene expression, proteomic, and microbiome analysis. By integrating conventional medical data including blood tests and imaging, we customize a plan to optimize each client’s health. We provide partial and whole genome tests to screen for pre-disposition to familial illnesses and for mutations associated with current or potential future illnesses. A whole genome test can be used to create a baseline, to look for trends and possible future changes as a way to monitor one’s wellness. We also provide health monitoring programs enabling clients to optimize their fitness by monitoring their over all physical well-being (medical, diet, social, and environmental influences). We also hope to gain insights for finding potential cures through our individualized clinical studies.
We offer one of the most comprehensive approaches to overcome obesity and the overweight problem by analyzing the underlying causes and providing practical, sustainable solutions that could empower clients to enjoy longer and healthier lives.
IRIS Wellness Labs is privately held, but has the potential to be listed on major stock exchanges such as the NASDAQ. If you would like more information or would like to invest, please contact Simon Chin at (408-806-7149).
Iris BioTechnologies Inc. (IRSB) is a publicly traded life sciences company with patented technologies providing one of the most comprehensive analysis to you and your physicians with the information to choose the best medical treatment regimen before the treatment begins. Iris enables precision healthcare, the future of medicine. Iris analyses the totality of who you are by looking at a combination of many things, including your nucleic acids such as DNA and RNA as well as proteins, family medical history, life style, and environmental exposure.
Iris is confident that we offer the best approach to enable physicians to treat diseases such as cancer through actionable integration of molecular profiling with clinical decision making, precision analysis of potential cancer recurrence and therapeutic effectiveness, along with matching to targeted therapies and therapies in clinical trials.
The Iris Nano-Biochip™ product pipeline includes: CancerChip™, PrenatalChip™, NeuroChip™ (Alzheimer’s and Parkinson diseases), MetabolicChip™ (Diabetes), CardioChip™, and Chips for veterinary, agricultural (e.g., biofuel development), environmental, and other applications. The Iris BioWindows™ artificial intelligence system provides big data and analysis for clinical applications, drug development, and stem cell research.
If you would like more information or would like to invest, please contact Simon Chin at (408-806-7149).